Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver ...

Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver ...

14 мар. 2024 г. · Use of Rezdiffra should be avoided in patients with decompensated cirrhosis. Patients should stop using Rezdiffra if they develop signs or ...

24 мар. 2024 г. · Rezdiffra is approved for adults with NASH who have moderate to advanced scarring of the liver, which is the case for an estimated 6 to 8 ...

28 окт. 2024 г. · The study enrolled 845 MASH patients with well-compensated cirrhosis and at least three metabolic risk factors, exceeding the enrollment target of 700 ...

15 мар. 2024 г. · High levels of lipids within the liver are associated with NASH and symptoms such as liver swelling, fibrosis, and cirrhosis. NASH resolution ...

22 окт. 2024 г. · Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH cirrhosis.

Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis.

Hepatic Impairment. Avoid use in patients with decompensated cirrhosis (consistent with moderate to severe hepatic impairment). Moderate or severe hepatic ...

15 июл. 2024 г. · 1. The safety and effectiveness of. Rezdiffra have not been established in patients with NASH cirrhosis. MEASTRO-NASH-. OUTCOMES is an ongoing ...